Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Foundayo vs Wegovy Pill: How the Two GLP-1 Pills Differ

Foundayo vs Wegovy pill is a match between two very different molecules that reach the same target. Both tablets act on the GLP-1 receptor, and both are approved in the US for weight management in certain adults. The Wegovy pill carries a peptide plus a helper called SNAC, while Foundayo carries a small molecule and lists no SNAC.

We found no trial that ran them against each other for weight, in a registry search that was not exhaustive, so neither can be named the winner from the data. This page compares approvals, trial results, label rules and warnings as of 15 November 2026.

On this page

Key facts

The molecules: the Wegovy pill holds semaglutide, a peptide. Foundayo holds orforglipron, a small molecule that is not a peptide.

Getting in: about 1% to 2% of the semaglutide in a tablet reaches the blood, with SNAC helping. About 77% of orforglipron did in a label study.

Journal results: minus 13.6% for the Wegovy pill at week 64, and minus 11.2% for Foundayo at its highest level at week 72, in separate trials.

Head to head: a registry search, not exhaustive, found no weight trial pairing them. The one match it found, ACHIEVE-3, was in type 2 diabetes, against oral semaglutide at diabetes strengths.

Status on 15 November 2026: both approved in the US. Only the Wegovy pill also has a heart outcome use.

Sources: Wegovy label on DailyMed, revised June 2026; Foundayo label on DailyMed; OASIS 4 paper (PMID 40934115); ATTAIN-1 paper (PMID 40960239); Lilly release on ACHIEVE-3; openFDA Foundayo search, 15 November 2026

How do Foundayo and the Wegovy pill differ?

They share a target and a warning, and differ on almost everything else. The table sets each fact from the two labels and FDA records next to each other.

Foundayo against the Wegovy pill, from the two US labels, FDA records and the EMA, checked 15 November 2026.
PointFoundayoWegovy pill
Active ingredientOrforglipron, from Eli LillySemaglutide, from Novo Nordisk
Kind of moleculeA small molecule with no peptide chainPeptide, a changed copy of the GLP-1 hormone
Weight of one moleculeAbout 902 g/mol (calcium salt form)About 4,114 g/mol
Absorption helperNone listed among its ingredientsSNAC
Share reaching the bloodAbout 77% in a label studyAbout 1% to 2%
Food rules on the labelFDA says no empty stomach is neededStrict empty-stomach rules
Main way the body clears itLiver enzyme CYP3A4, with interaction rulesNo CYP3A4 rule on the label
FDA class at approvalNew molecular entity, 1 April 2026New form of an approved drug, 22 December 2025
US approved usesWeight management onlyWeight management, plus lowering major heart event risk in some adults
Europe, 15 November 2026Committee backed it in October 2026; final decision pendingEMA lists tablets as a form for adults
Boxed warningThyroid C-cell tumorsThyroid C-cell tumors

The food rules differ, but this page does not repeat them as steps. They are set out on each label, and a prescriber explains them.

Sources: Foundayo label on DailyMed; Wegovy label on DailyMed, revised June 2026; FDA news release on Foundayo, 1 April 2026; openFDA record, NDA 218316 (Wegovy tablets); openFDA record, NDA 220934 (Foundayo); EMA page on Foundayo

Why does one pill need a helper and the other does not?

Because one is a peptide and one is not. The Wegovy tablet is made with SNAC, an absorption helper, while the Foundayo label lists no such helper. Our oral semaglutide episode explains what SNAC does in the stomach, and our Foundayo episode explains how orforglipron acts on the receptor.

Sources: Wegovy label on DailyMed, revised June 2026; Foundayo label on DailyMed

Which pill lost more weight in trials?

In their own journal papers, the Wegovy pill posted the bigger average number, but the two trials cannot be ranked. They differed in length, size and people. The journal results below count everyone who was randomized, even people who stopped. The company figures are adherence analyses, which estimate results for people who kept to treatment, and they come from news releases.

Main weight trials of the two pills: journal results first, then company-reported adherence analyses.
TrialPeopleLengthJournal resultCompany figure
OASIS 4 (Wegovy pill)307 people without diabetes (205 on the pill, 102 on placebo)Main result at week 64Minus 13.6% against minus 2.2% on placebo, counting everyone randomizedNovo reports 16.6% for people who kept taking it (adherence analysis, no placebo figure given)
ATTAIN-1 (Foundayo)3,127 adults with obesity and no diabetesMain result at week 72Minus 11.2% at the highest level tested against minus 2.1% on placebo, counting everyone randomizedLilly reports 12.4% against 0.9% for people who stayed on the highest level (efficacy analysis)

OASIS 4. It was double-blind and placebo-controlled, at 22 sites in four countries, in people with obesity, or overweight plus a weight-related problem. The main readout came at week 64 of a 71-week trial. With 307 people, it was about a tenth the size of ATTAIN-1.

ATTAIN-1. It tested three levels of orforglipron against placebo for 72 weeks, along with diet and activity. The two lower levels averaged minus 7.5% and minus 8.4%. The minus 11.2% figure belongs to the highest level only.

Each figure is an average across a group and cannot predict what one person would see. For how a pill compares with a shot of a different drug, see our orforglipron vs tirzepatide guide.

Sources: OASIS 4 paper (PMID 40934115); ATTAIN-1 paper (PMID 40960239); Novo Nordisk release, 22 December 2025; Lilly release on the Foundayo approval

Has anyone tested Foundayo against the Wegovy pill directly?

Not for weight, as far as we could find. Lilly calls ACHIEVE-3 the first and only head-to-head Phase 3 trial of two oral GLP-1 drugs for type 2 diabetes. It put orforglipron against oral semaglutide at the strengths approved for diabetes. That is not the Wegovy pill, and the trial was in a different group of people.

A ClinicalTrials.gov search for orforglipron with oral semaglutide returned only ACHIEVE-3. That search was not exhaustive, so we cannot say for sure that no weight trial pairing them exists. What we can say is that no such trial appeared in the sources we checked on 15 November 2026.

Sources: Lilly release on ACHIEVE-3; OASIS 4 paper (PMID 40934115); ATTAIN-1 paper (PMID 40960239)

How do the two labels differ beyond food rules?

The labels split on more than meals. The table lists the points that differ.

Label points that differ between Foundayo and the Wegovy tablet, read from DailyMed, November 2026.
Label pointFoundayoWegovy tablet
Blood levelsNot compared in the sources we usedLevels from the tablet vary more from person to person than from the Wegovy shot
Other medicinesInteraction rules for drugs that block or speed up CYP3A4No CYP3A4 rule
Specific interaction namedFlags a possible effect on hormonal birth control pillsA semaglutide tablet raised levothyroxine (a thyroid hormone pill) exposure by 33% in a study
Breast milkNo SNAC in the tabletSNAC or its byproducts were found in human milk
Heart rateAverage rise of 4 to 5 beats per minute against 0.5 on placebo, listed as a side effectListed as a separate warning
Heart outcomesNo heart outcome useApproved to lower major heart event risk in adults with heart disease and excess weight

The labels list each interaction in full, and a pharmacist or prescriber can check them against other medicines.

Sources: Foundayo label on DailyMed; Wegovy label on DailyMed, revised June 2026

How do the side effects and warnings compare?

Gut effects lead for both. In OASIS 4, 74.0% of people on the Wegovy pill reported gut side effects, against 42.2% on placebo. In ATTAIN-1, gut effects were the most common and mostly mild to moderate, and 5.3% to 10.3% of people stopped orforglipron because of side effects, against 2.7% on placebo.

Shared warnings. Both labels warn about an inflamed pancreas (pancreatitis), severe stomach and bowel reactions, kidney harm when the body loses fluid, gallbladder disease and serious allergic reactions. Both also list low blood sugar when used with insulin or drugs that push insulin release, eye problems in type 2 diabetes, and lung aspiration during anesthesia or deep sedation. Each label says using it with another GLP-1 receptor agonist is not recommended.

One warning, two stories. Both carry a boxed thyroid C-cell tumor warning, and both rule out anyone whose own or family history includes medullary thyroid cancer, or MEN 2. For semaglutide, the warning comes from rats and mice that grew these tumors. Orforglipron does not act on the rodent GLP-1 receptor and caused no rodent tumors, so those tests could not show the same risk. For both drugs, whether the risk applies to people has not been determined.

Small group numbers like these cannot predict side effects for one person. Our GLP-1 side effects guide covers the class more broadly, and a licensed clinician is the one to judge risk for a patient.

Sources: OASIS 4 paper (PMID 40934115); ATTAIN-1 paper (PMID 40960239); Foundayo label on DailyMed; Wegovy label on DailyMed, revised June 2026; FDA news release on Foundayo, 1 April 2026

Where are Foundayo and the Wegovy pill approved?

United States. The Wegovy pill came first. It won FDA approval on 22 December 2025, classed as a new form of semaglutide, which was already approved. Novo Nordisk describes it as the first GLP-1 pill approved for weight management, and says the approval rested on the OASIS trials plus SELECT, a heart outcome trial. Foundayo won FDA approval on 1 April 2026 as a molecule never approved before. It won approval 50 days after filing under a priority voucher pilot, which the FDA calls its fastest new molecule approval since 2002.

What each covers. Both carry the same weight use: with a lower-calorie diet and more exercise, they help adults who have obesity, or extra weight and a health problem tied to it, lose weight and hold it off. Only the Wegovy pill adds a heart use, cutting the chance of a major heart event such as a heart attack or stroke in adults who have both heart disease and excess weight. On 15 November 2026, FDA records listed no US type 2 diabetes approval for Foundayo.

Europe. An EMA committee backed Foundayo on 15 October 2026 for weight management and type 2 diabetes, and the final decision was still pending in mid-November. The EMA page for Wegovy now lists tablets as a form, for adults only.

Status facts were rechecked against FDA records, both labels and the EMA when this was written, as our medical review policy requires. Those records can trail real events by a few weeks.

Sources: openFDA record, NDA 218316 (Wegovy tablets); openFDA Foundayo search, 15 November 2026; Novo Nordisk release, 22 December 2025; FDA news release on Foundayo, 1 April 2026; Foundayo label on DailyMed; Wegovy label on DailyMed, revised June 2026; EMA page on Foundayo

What else do people ask about Foundayo vs Wegovy?

What is the main difference between Foundayo and the Wegovy pill?+

The molecule. The Wegovy pill holds semaglutide, a peptide copy of the GLP-1 hormone that is made with an absorption helper called SNAC. Foundayo holds orforglipron, a small molecule rather than a peptide, and no SNAC appears on its label. Both act on the GLP-1 receptor.

Which pill causes more weight loss, Foundayo or the Wegovy pill?+

Their trials cannot settle it. In its journal paper, the Wegovy pill averaged minus 13.6% at week 64 in 307 people. In its own paper, Foundayo averaged minus 11.2% at its highest level at week 72 in 3,127 people. The trials differed in length, size and people, so the numbers are not a fair race.

Has Foundayo been tested head to head against the Wegovy pill?+

Not that we found. The one head-to-head Phase 3 trial we found, ACHIEVE-3, was in type 2 diabetes. It tested orforglipron against oral semaglutide at the strengths used for diabetes, not against the Wegovy pill. A registry search pairing the two drugs returned only ACHIEVE-3, though that search was not exhaustive.

Are Foundayo and the Wegovy pill both approved in the US?+

Yes. The Wegovy pill won FDA approval on 22 December 2025, as a new form of semaglutide. Foundayo won FDA approval on 1 April 2026, as a molecule never approved before. As of 15 November 2026 both are prescription drugs in the US.

What is each pill approved for in the US?+

Both are approved in the US, alongside diet and exercise, to bring down excess weight and hold the loss in adults who have obesity, or extra weight plus a related health problem. Only the Wegovy pill has a second use: lowering major heart event risk in some adults with established heart disease.

Do Foundayo and the Wegovy pill have the same side effects?+

Gut side effects are the most common for both. In OASIS 4, 74.0% on the Wegovy pill had gut side effects against 42.2% on placebo. In ATTAIN-1, 5.3% to 10.3% stopped orforglipron because of side effects, against 2.7% on placebo. Both labels warn about pancreatitis, gallbladder disease, kidney injury and serious allergic reactions.

Why do both pills carry a thyroid warning?+

Both labels open with a boxed thyroid C-cell tumor warning, and both rule out anyone whose own or family history includes medullary thyroid cancer or MEN 2. Semaglutide caused these tumors in rats and mice. Orforglipron does not act on the rodent GLP-1 receptor, so rodent tests could not show that risk. For both, whether it applies to people is not known.

Is Foundayo approved in Europe?+

Not yet, as of 15 November 2026. A committee of the EMA backed it on 15 October 2026, for weight management and type 2 diabetes, while the European Commission had yet to decide. The EMA page for Wegovy lists tablets as a form for adults.

Can Foundayo and the Wegovy pill be taken together?+

Both labels say using the drug with another GLP-1 receptor agonist is not recommended. Any question about combining medicines is one for a licensed clinician.

Sources: Foundayo label on DailyMed; Wegovy label on DailyMed, revised June 2026; OASIS 4 paper (PMID 40934115); ATTAIN-1 paper (PMID 40960239); Lilly release on ACHIEVE-3; openFDA record, NDA 218316 (Wegovy tablets); openFDA record, NDA 220934 (Foundayo); EMA page on Foundayo

So what is actually different?

The Wegovy pill is a borrowed hormone that travels with SNAC, and Foundayo is a newly approved small molecule whose label lists no SNAC. Their labels set different rules, they share one thyroid warning, and their trials cannot be compared fairly. The one head-to-head Phase 3 trial we found, in a search that was not exhaustive, was in type 2 diabetes, against oral semaglutide at diabetes strengths.

On YouTube, Molecule Mechanics turns drug science into short animations and links its sources below each video. This comparison follows the two labels, the trial papers, FDA records and the company releases as of 15 November 2026. A synthetic ElevenLabs voice narrates, and the art is drawn for the channel. Another page in the series compares compounded tirzepatide with Zepbound, and our Wegovy vs Ozempic guide covers the two semaglutide shots.

If any number here seems wrong, tell us through our corrections policy and we will check it.

Browse every Molecule Mechanics upload on YouTube

Sources: Novo Nordisk release, 22 December 2025; Lilly release on ACHIEVE-3; Molecule Mechanics channel

Written to inform, not to advise. Every fact traces to the two US labels, trial papers, FDA and EMA records or company releases, listed at the end of each section. Nothing here picks a pill for anyone, and that decision rests with a licensed clinician.

Sources

  1. 1.FOUNDAYO (orforglipron) label via DailyMed, labeling effective July 2026: orforglipron calcium molecular weight 902.0 g/mol; absolute bioavailability of 77% in the label study; inactive ingredients with no SNAC; no clinically relevant food effect; broken down mainly by the liver enzyme CYP3A4, with interaction rules; oral hormonal contraceptives flagged; heart rate rise of 4 to 5 beats per minute against 0.5 on placebo, listed under adverse reactions; boxed thyroid warning, with orforglipron not active in rats or mice and no rodent tumors; weight indication only; use with another GLP-1 receptor agonist not recommended.
  2. 2.WEGOVY label via DailyMed, effective 18 June 2026 (tablet sections, rechecked 15 November 2026): semaglutide is a GLP-1 analogue sharing 94% of its sequence with human GLP-1, molecular weight 4,113.58 g/mol, backbone made by yeast fermentation; tablets made with SNAC, an absorption enhancer; absorbed mainly in the stomach; about 1% to 2% bioavailability; blood levels vary more than with the shot; empty-stomach rules; no CYP3A4 rule; levothyroxine exposure up 33% in a study; SNAC found in human milk; heart rate increase listed as a warning; weight and major heart event indications; boxed thyroid warning from rodent tumors; pancreatitis, gallbladder, kidney injury and allergic reaction warnings.
  3. 3.FDA news release dated 1 April 2026: Foundayo approved under the Commissioner National Priority Voucher pilot, 50 days after filing, the fastest approval of a new molecular entity since 2002; the FDA describes a pill that only partly switches on the GLP-1 receptor and needs no empty stomach; warnings for pancreatitis, severe gut reactions and more.
  4. 4.openFDA Drugs@FDA, NDA 218316 (Wegovy tablets): original approval 22 December 2025, Type 3, new dosage form; latest labeling supplement 18 June 2026. Queried 15 November 2026.
  5. 5.openFDA Drugs@FDA, NDA 220934 (Foundayo): first approved 1 April 2026 as a Type 1 new molecular entity; one labeling supplement, 4 August 2026; no US type 2 diabetes approval listed. Queried 15 November 2026; openFDA can lag a few weeks.
  6. 6.Novo Nordisk news release, 22 December 2025: the Wegovy pill is the first oral GLP-1 receptor agonist approved for weight management; approval based on the OASIS program and the SELECT trial; 16.6% mean weight loss in OASIS 4 when treatment was adhered to (trial product estimand). Company source.
  7. 7.Eli Lilly news release on the Foundayo approval: orforglipron was found by Chugai Pharmaceutical and licensed by Lilly in 2018; at the highest strength, people who stayed on treatment in ATTAIN-1 lost 12.4% on average against 0.9% on placebo (efficacy estimand). Company source.
  8. 8.Eli Lilly news release on ACHIEVE-3: the first and only head-to-head Phase 3 trial of two oral GLP-1 receptor agonists for type 2 diabetes, with oral semaglutide at approved diabetes strengths. Company source; release date not confirmed.
  9. 9.OASIS 4, randomized, double-blind, placebo-controlled trial of oral semaglutide at 22 sites in four countries, PMID 40934115, abstract read 15 November 2026: 205 on oral semaglutide and 102 on placebo, people without diabetes; mean weight change at week 64 of minus 13.6% against minus 2.2%; gut side effects 74.0% against 42.2%.
  10. 10.ATTAIN-1, Phase 3, multinational, randomized, double-blind trial of orforglipron, PMID 40960239, abstract read 15 November 2026: 3,127 adults with obesity and no diabetes; mean weight change at week 72 of minus 7.5%, minus 8.4% and minus 11.2% across three levels, against minus 2.1% on placebo; 5.3% to 10.3% stopped for side effects against 2.7%; gut effects most common, mostly mild to moderate.
  11. 11.Buckley and colleagues, 2018, PMID 30429357 (authors from Novo Nordisk): peptides are poorly absorbed through the gut and broken down by enzymes; semaglutide absorption from the tablet happens in the stomach near the tablet and needs SNAC.
  12. 12.European Medicines Agency, Foundayo page, read 15 November 2026: positive CHMP opinion on 15 October 2026 for weight management and type 2 diabetes; European Commission decision not shown. The EMA Wegovy page lists tablets as an available form for adults.